• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新加坡精神分裂症患者和抑郁症患者的 SF-6D、EQ-5D 和 HUI3 效用测量的可靠性和有效性比较。

A comparison of the reliability and validity of SF-6D, EQ-5D and HUI3 utility measures in patients with schizophrenia and patients with depression in Singapore.

机构信息

Research Division, Institute of Mental Health, Buangkok Green Medical Park, 10 Buangkok View, 539747, Singapore.

Research Division, Institute of Mental Health, Buangkok Green Medical Park, 10 Buangkok View, 539747, Singapore.

出版信息

Psychiatry Res. 2019 Apr;274:400-408. doi: 10.1016/j.psychres.2019.02.077. Epub 2019 Mar 1.

DOI:10.1016/j.psychres.2019.02.077
PMID:30852434
Abstract

There is limited evidence of a direct comparison of the psychometric performance of generic preference-based measures in patients with mental illness in an Asian patient population. The current study aimed to compare the test-retest reliability, convergent and known-group validity and magnitude of change in scores of the EuroQol Five-Dimension, Health Utility Index Mark 3 (HUI3) and Short-Form Six-Dimension (SF-6D) measures in patients with depression and patients with schizophrenia spectrum disorder. 500 patients were recruited from a tertiary psychiatric institution in Singapore. The Schizophrenia Quality of Life Scale (SQLS), 8-item Patient Health Questionnaire, Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), and Positive and Negative Syndrome Scale were also included. In the schizophrenia sample, the SF-6D was found to have higher test-retest validity, convergent validity with SQLS domain scores, known-group validity and magnitude of change in scores over 6-month follow up than other measures. In the depression sample, the HUI3 was found to have higher test-retest reliability, convergent validity with Q-LES-Q, known group validity and magnitude of change in scores than other measures. Results suggest that the SF-6D and HUI3 to be more suitable as a utility measure for patients with schizophrenia and depression in an Asian patient population.

摘要

在亚洲患者人群中,针对精神疾病患者,很少有直接比较通用偏好量表心理测量性能的证据。本研究旨在比较在抑郁症患者和精神分裂症谱系障碍患者中,欧洲五维健康量表(EQ-5D)、健康效用指数标记 3 版(HUI3)和简短六维健康量表(SF-6D)测量的重测信度、聚合和已知组有效性以及评分变化幅度。从新加坡的一家三级精神病院招募了 500 名患者。还包括精神分裂症生活质量量表(SQLS)、8 项患者健康问卷、生活质量享受和满意度问卷(Q-LES-Q)以及阳性和阴性综合征量表。在精神分裂症样本中,SF-6D 具有更高的重测信度、与 SQLS 领域得分的聚合效度、已知组有效性以及在 6 个月随访期间的评分变化幅度,优于其他测量。在抑郁症样本中,HUI3 具有更高的重测信度、与 Q-LES-Q 的聚合效度、已知组有效性和评分变化幅度,优于其他测量。结果表明,SF-6D 和 HUI3 更适合作为亚洲患者人群中精神分裂症和抑郁症患者的效用测量工具。

相似文献

1
A comparison of the reliability and validity of SF-6D, EQ-5D and HUI3 utility measures in patients with schizophrenia and patients with depression in Singapore.新加坡精神分裂症患者和抑郁症患者的 SF-6D、EQ-5D 和 HUI3 效用测量的可靠性和有效性比较。
Psychiatry Res. 2019 Apr;274:400-408. doi: 10.1016/j.psychres.2019.02.077. Epub 2019 Mar 1.
2
A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.一项针对精神分裂症患者的研究中SF-6D与EQ-5D效用评分的比较。
J Ment Health Policy Econ. 2009 Mar;12(1):27-31.
3
EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.症状性良性甲状腺结节的 EQ-5D-5L 和 SF-6D 效用测量:可接受性和心理测量评估。
Patient. 2017 Aug;10(4):447-454. doi: 10.1007/s40271-017-0220-5.
4
A review of the psychometric properties of generic utility measures in multiple sclerosis.多发性硬化症中通用效用测量的心理测量特性综述。
Pharmacoeconomics. 2014 Aug;32(8):759-73. doi: 10.1007/s40273-014-0167-5.
5
Mapping the schizophrenia quality of life scale to EQ-5D, HUI3 and SF-6D utility scores in patients with schizophrenia.将精神分裂症患者生活质量量表与EQ-5D、HUI3及SF-6D效用评分进行映射分析
Expert Rev Pharmacoecon Outcomes Res. 2023 Jul-Dec;23(7):813-821. doi: 10.1080/14737167.2023.2215430. Epub 2023 May 27.
6
Mapping the Positive and Negative Syndrome Scale scores to EQ-5D-5L and SF-6D utility scores in patients with schizophrenia.将阳性与阴性症状量表评分映射至精神分裂症患者的 EQ-5D-5L 和 SF-6D 效用评分。
Qual Life Res. 2019 Jan;28(1):177-186. doi: 10.1007/s11136-018-2037-7. Epub 2018 Oct 31.
7
A study of the construct validity of the Health Utilities Index Mark 3 (HUI3) in patients with schizophrenia.精神分裂症患者健康效用指数3级(HUI3)的结构效度研究。
Qual Life Res. 2006 Jun;15(5):889-98. doi: 10.1007/s11136-005-5745-8.
8
Measuring the Burden of Schizophrenia Using Clinician and Patient-Reported Measures: An Exploratory Analysis of Construct Validity.使用临床医生和患者报告的测量方法衡量精神分裂症的负担:对构念效度的探索性分析。
Patient. 2019 Aug;12(4):405-417. doi: 10.1007/s40271-019-00358-x.
9
Mapping the PHQ-8 to EQ-5D, HUI3 and SF6D in patients with depression.将 PHQ-8 映射到抑郁症患者的 EQ-5D、HUI3 和 SF6D 上。
BMC Psychiatry. 2021 Sep 13;21(1):451. doi: 10.1186/s12888-021-03463-0.
10
Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).终末期肾病(ESRD)患者中基于偏好的EQ-5D-5L与SF-6D的比较。
Eur J Health Econ. 2015 Dec;16(9):1019-26. doi: 10.1007/s10198-014-0664-7. Epub 2014 Dec 18.

引用本文的文献

1
Developing an EQ-5D-5L Value Set for Singapore.为新加坡制定EQ-5D-5L价值集。
Pharmacoeconomics. 2025 Aug 29. doi: 10.1007/s40273-025-01519-7.
2
Validation and comparison of EQ-5D-5L and SF-6Dv1 in myopic patients requiring corneal refractive surgery in China.中国近视患者角膜屈光手术中EQ-5D-5L与SF-6Dv1的验证与比较
Health Qual Life Outcomes. 2025 Aug 22;23(1):78. doi: 10.1186/s12955-025-02411-w.
3
PeerTECH: a randomized controlled trial of a peer-led mobile health intervention to improve medical and psychiatric self-management for persons with serious mental illness.
同伴技术:一项随机对照试验,该试验采用由同伴主导的移动健康干预措施,以改善严重精神疾病患者的医疗和精神自我管理。
Mhealth. 2025 Jun 30;11:28. doi: 10.21037/mhealth-24-64. eCollection 2025.
4
Health-related quality of life in psychiatric outpatients: a cross-sectional study of associations with symptoms, diagnoses, and employment status.精神科门诊患者的健康相关生活质量:一项与症状、诊断和就业状况关联的横断面研究。
Qual Life Res. 2024 Nov;33(11):3093-3105. doi: 10.1007/s11136-024-03748-3. Epub 2024 Aug 7.
5
Factors associated with health-related quality of life in long-stay inpatients with chronic schizophrenia.长期住院慢性精神分裂症患者健康相关生活质量的相关因素。
PCN Rep. 2022 Sep 8;1(3):e42. doi: 10.1002/pcn5.42. eCollection 2022 Sep.
6
Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China.在中国淋巴瘤患者中,EQ-5D-5L 和 SF-6Dv2 的心理计量学性能。
Eur J Health Econ. 2024 Dec;25(9):1471-1484. doi: 10.1007/s10198-024-01672-4. Epub 2024 Mar 7.
7
Comparison of the measurement properties of the EQ-5D-5L and SF-6Dv2 among overweight and obesity populations in China.比较 EQ-5D-5L 和 SF-6Dv2 在超重和肥胖人群中的测量特性。
Health Qual Life Outcomes. 2023 Oct 31;21(1):118. doi: 10.1186/s12955-023-02202-1.
8
A culturally adapted manual-assisted problem-solving intervention (CMAP) for adults with a history of self-harm: a multi-centre randomised controlled trial.一种文化适应性的手动辅助问题解决干预(CMAP)对有自我伤害史的成年人:一项多中心随机对照试验。
BMC Med. 2023 Jul 31;21(1):282. doi: 10.1186/s12916-023-02983-8.
9
Clinical Outcome Assessment Instruments in Schizophrenia: A Scoping Literature Review with a Focus on the Potential of Patient-reported Outcomes.精神分裂症的临床结局评估工具:一项以患者报告结局的潜力为重点的范围性文献综述
Innov Clin Neurosci. 2023 Spring;20(4-6):14-33.
10
Assessing the validity and responsiveness of a generic preference quality of life measure in the context of posttraumatic stress disorder.评估通用偏好生活质量量表在创伤后应激障碍背景下的有效性和反应性。
Qual Life Res. 2023 Oct;32(10):2817-2827. doi: 10.1007/s11136-023-03432-y. Epub 2023 May 14.